Terms: = Ovarian cancer AND MNX1, HB9, 3110, ENSG00000130675, P50219, HLXB9
22 results:
1. Assessment of Homologous Recombination Deficiency in ovarian cancer.
Garg V; Oza AM
Clin Cancer Res; 2023 Aug; 29(16):2957-2960. PubMed ID: 37347464
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive network analysis of dysregulated genes revealed mnx1-AS1/hsa-miR-4697-3p/HOXB13 axis in ovarian cancer chemotherapy response.
Wu A; Liu J; Zhang X; Niu C; Shu G; Yin G
Cancer Sci; 2022 Aug; 113(8):2627-2641. PubMed ID: 35639251
[TBL] [Abstract] [Full Text] [Related]
3. LncRNA mnx1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis.
Shen Y; Lv M; Fang Y; Lu J; Wu Y
J Ovarian Res; 2021 Nov; 14(1):161. PubMed ID: 34789303
[TBL] [Abstract] [Full Text] [Related]
4. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
[TBL] [Abstract] [Full Text] [Related]
5. Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar.
Kalsi JK; Ryan A; Gentry-Maharaj A; Margolin-Crump D; Singh N; Burnell M; Benjamin E; Apostolidou S; Habib M; Massingham S; Karpinskyj C; Woolas R; Widschwendter M; Fallowfield L; Campbell S; Skates S; McGuire A; Parmar M; Jacobs I; Menon U
Trials; 2021 Jan; 22(1):88. PubMed ID: 33494753
[TBL] [Abstract] [Full Text] [Related]
6. Half-dose bevacizumab experience in relapsed ovarian cancer patients in Turkey due to formal regulations: similar effectiveness with lower rate of hypertension.
Kose F; Alemdaroglu S; Mertsoylu H; Besen AA; Guler OC; Simsek SY; Erbay G; Onal C; Celik H
J BUON; 2020; 25(4):1928-1934. PubMed ID: 33099934
[TBL] [Abstract] [Full Text] [Related]
7. Application of the optimized and validated LC-MS method for simultaneous quantification of tryptophan metabolites in culture medium from cancer cells.
Sadok I; Rachwał K; Staniszewska M
J Pharm Biomed Anal; 2019 Nov; 176():112805. PubMed ID: 31415991
[TBL] [Abstract] [Full Text] [Related]
8. Long non-coding RNA mnx1-AS1 promotes hepatocellular carcinoma proliferation and invasion through targeting miR-218-5p/COMMD8 axis.
Ji D; Wang Y; Sun B; Yang J; Luo X
Biochem Biophys Res Commun; 2019 Jun; 513(3):669-674. PubMed ID: 30982576
[TBL] [Abstract] [Full Text] [Related]
9. Long noncoding RNA mnx1-AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway.
Liu H; Han L; Liu Z; Gao N
J Cell Physiol; 2019 Aug; 234(8):13843-13850. PubMed ID: 30618167
[TBL] [Abstract] [Full Text] [Related]
10. E2F1-mediated mnx1-AS1-miR-218-5p-SEC61A1 feedback loop contributes to the progression of colon adenocarcinoma.
Ye Y; Gu B; Wang Y; Shen S; Huang W
J Cell Biochem; 2019 Apr; 120(4):6145-6153. PubMed ID: 30362161
[TBL] [Abstract] [Full Text] [Related]
11. LncRNA mnx1-AS1 promotes the progression of cervical cancer through activating MAPK pathway.
Liu X; Yang Q; Yan J; Zhang X; Zheng M
J Cell Biochem; 2019 Mar; 120(3):4268-4277. PubMed ID: 30302806
[TBL] [Abstract] [Full Text] [Related]
12. lncRNA mnx1-AS1 Promotes Glioblastoma Progression Through Inhibition of miR-4443.
Gao Y; Xu Y; Wang J; Yang X; Wen L; Feng J
Oncol Res; 2019 Feb; 27(3):341-347. PubMed ID: 29678219
[TBL] [Abstract] [Full Text] [Related]
13. Overexpression of lncRNA mnx1-AS1 is associated with poor clinical outcome in epithelial ovarian cancer.
Li AH; Zhang HH
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(24):5618-5623. PubMed ID: 29271994
[TBL] [Abstract] [Full Text] [Related]
14. Expression of OTUB1 in hepatocellular carcinoma and its effects on HCC cell migration and invasion.
Ni Q; Chen J; Li X; Xu X; Zhang N; Zhou A; Zhou B; Lu Q; Chen Z
Acta Biochim Biophys Sin (Shanghai); 2017 Aug; 49(8):680-688. PubMed ID: 28575188
[TBL] [Abstract] [Full Text] [Related]
15. Long Noncoding RNA mnx1-AS1 Knockdown Inhibits Cell Proliferation and Migration in ovarian cancer.
Lv Y; Li H; Li F; Liu P; Zhao X
Cancer Biother Radiopharm; 2017 Apr; 32(3):91-99. PubMed ID: 28414551
[TBL] [Abstract] [Full Text] [Related]
16. Validation of Revised FIGO Staging Classification for cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
[TBL] [Abstract] [Full Text] [Related]
17. ovarian Suspension With Adjustable Sutures: An Easy and Helpful Technique for Facilitating Laparoendoscopic Single-Site Gynecologic Surgery.
Chen KH; Chen LR; Seow KM
J Minim Invasive Gynecol; 2015; 22(5):767-75. PubMed ID: 25757814
[TBL] [Abstract] [Full Text] [Related]
18. Image-guided ovarian mass biopsy: efficacy and safety.
Thabet A; Somarouthu B; Oliva E; Gervais DA; Hahn PF; Lee SI
J Vasc Interv Radiol; 2014 Dec; 25(12):1922-1927.e1. PubMed ID: 25241300
[TBL] [Abstract] [Full Text] [Related]
19. Discrepant expression of carboxy- and aminoterminal propeptides of type I procollagen predicts poor clinical outcome in epithelial ovarian cancer.
Simojoki M; Santala M; Risteli J; Kauppila A
Gynecol Oncol; 2003 Mar; 88(3):358-62. PubMed ID: 12648587
[TBL] [Abstract] [Full Text] [Related]
20. Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies.
Dehaven K; Taylor DD; Gercel-Taylor C
Int J Gynecol Cancer; 2002; 12(6):715-9. PubMed ID: 12445248
[TBL] [Abstract] [Full Text] [Related]
[Next]
